The orphan nuclear receptor small heterodimer partner (SHP; NR0B2) interacts with a diverse array of transcription factors and regulates a variety of cellular events such as cell proliferation, differentiation, and metabolism. However, the role of SHP in bone formation has not yet been elucidated. SHP expression is significantly increased during osteoblast differentiation, and its expression is partially regulated by bone morphogenetic protein 2 (BMP-2), which plays an important role in bone formation. In our study, inhibition of SHP expression significantly repressed BMP-2-induced osteoblast differentiation and ectopic bone formation. In accordance with these in vitro and in vivo results, osteoblast differentiation in SHP À/À mice primary osteoblasts was significantly repressed, and the mice showed decreased bone mass resulting from decreased numbers of osteoblasts. Finally, SHP physically interacts and forms a complex with runt-related transcription factor 2 (Runx2) on the osteocalcin gene promoter, and overexpression of SHP increased Runx2 transactivity via competition with histone deacetylase 4 (HDAC4), an enzyme that inhibits DNA binding of Runx2 to its target genes. Taken together, these results indicate that SHP acts as a novel positive regulator of bone formation by augmenting osteoblast differentiation through regulation of the transcriptional activity of Runx2. ß
Introduction
T he atypical orphan nuclear receptor (NR) SHP is a versatile protein with broad cellular functions. Structurally, SHP has a putative ligand-binding domain (LBD) that lacks a classic DNAbinding domain (DBD) and harbors two functional LXXLL-like motifs, which are typical of NR-binding proteins.
(1) SHP interacts with various nuclear receptors and transcription factors, such as the estrogen receptor (ER), peroxisome proliferator-activated receptor (PPAR), retinoic acid receptor (RAR), liver X receptor (LXR), Nur77, c-Jun, Smad, histone deacetylase 1 (HDAC1), and the Swi/Snf/mSin3a corepressor complex. With the exception of PPAR, SHP acts to downregulate the transcriptional activity of these factors. (2, 3) These findings suggest that as a transcriptional coregulator, SHP participates in a complex regulatory network comprised of a variety of NRs and transcription factors. Recently, studies have focused on the role of SHP in metabolism or homeostasis. (4) (5) (6) (7) However, its function on bone metabolism has not yet been described. Bone formation is a well-orchestrated process of lineagespecific differentiation events. (8) Osteoblasts, which play pivotal roles in bone formation, are derived from pluripotent mesenchymal stem cells that have the capacity to differentiate into myocytes, adipocytes, and chondrocytes. (9) These stem cells can differentiate into mature osteoblasts that possess the necessary components to form bone matrix and allow subsequent mineralization. Osteoblast differentiation is controlled by various hormones and cytokines, such as bone morphogenetic proteins (BMPs), and multiple transcription factors such as Runx2, Osx, Dlx5, Msx2, Twist, AP1 (Fos/Jun), Krox-20, Sp3, and ATF4.
factor b (TGF-b) superfamily, the signal transduction by BMPs occurs through the activation of serine/threonine kinase receptors, which are classified as either type I or type II. After ligand binding, they form a heterotetrameric activated receptor complex and relay the signal from the receptor to target genes in the nucleus. Runx2, also called Cbfa1, is a member of the runt domain gene family. (13) These proteins play a major role in osteoblast differentiation by promoting the differentiation of undifferentiated mesenchymal cells into osteoblasts through regulation of various factors such as type I collagen (Col I), osteopontin (OPN), bone sialoprotein (BSP), and osteocalcin (OC). (14) Runx2 has been shown to induce alkaline phosphatase (ALP) activity, expression of bone matrix protein genes, and mineralization in immature mesenchymal cells and osteoblastic cells in vitro. (15) (16) (17) During osteoblast differentiation, Runx2 interacts with diverse transcription factors (18) and recruits both coactivators (e.g., p300, HES-1, and YAP) and corepressors (e.g., TLE, mSin3a, and HDACs) to form a complex on its target promoter. (19) (20) (21) (22) Recently, it has been reported that various NRs are involved in osteoblast differentiation and bone formation. Activation of androgen receptors stimulates BSP gene transcription via cAMP response element (CRE) and AP1/glucocorticoid response elements (GRE). (23) Estrogen prevents bone loss via ERa, (24) and estrogen receptor-related receptor a (ERRa) regulates osteopontin expression through a noncanonical ERRa response element. (25) In this study we investigated the effects of the orphan nuclear receptor, SHP in osteoblast differentiation, and our results show that SHP promotes osteoblast differentiation and bone formation via regulation of Runx2 transactivity.
Materials and Methods

Plasmid constructions
The reporter constructs, À1.3 kb OG2-Luc and 6ÂOSE-Luc, were kindly provided by Dr RT Fransceschi (University of Michigan School of Dentistry, Ann Arbor, MI, USA). The SHP-Luc construct was described previously. (26) Runx2 expression constructs were kindly provided by Dr KY Lee (Chonnam National University, Republic of Korea). The SHP expression construct was described previously. (27) pcDNA3/HA-ALK2, À3, À5, and À6 constructs were kindly provided by Dr T Imamura (JFCR Cancer Institute, Japan). The pBJ5.1/Flag-HDAC3 and -4 constructs were kindly provided by Dr H Kook (Chonnam National University, Republic of Korea). The HDAC4 siRNA constructs were constructed by ligation of a 60-mer double-stranded oligonucleotide containing 5'-AATGTACGACGCCAAAGAT-3' of the HDAC4 cDNA sequence into the pSUPER vector digested with Bgl II and Xho I.
Preparation of primary osteoblasts
Calvariae were isolated from 10-day-old neonatal mice and digested with 0.1% collagenase (Roche, Germany) at 378C for 30 minutes. The digested calvariae were sequentially digested four times. (30) The last fractions were collected and used as primary osteoblasts.
Cell culture and induction of osteoblast differentiation C2C12 cells were maintained in DMEM (Hyclone, Logan, UT, USA), and C3H10T1/2 and MC3T3-E1 cells and primary osteoblasts were maintained in a-minimal essential medium (a-MEM, Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS, Hyclone) and antibiotics (Hyclone). Differentiation of osteoblasts was induced by 200 ng/mL recombinant human bone morphogenetic protein 2 (BMP-2, R&D Systems, Minneapolis, MN, USA), 50 mg/mL ascorbic acid (AA), and 5 mM b-glycerophosphate (b-GP).
Transient transfection assay
Transient transfections using Lipofectamine Plus (Invitrogen, Carlsbad, CA, USA) were carried out as described previously. (28) As an internal control, cytomegalovirus (CMV) b-galactosidase plasmid was cotransfected in each transfection experiment, and luciferase activity was normalized to b-galactosidase activity.
RT-PCR analysis
RT-PCR was performed using 0.8 mg of total RNA. Each reaction consisted of initial denaturation at 948C for 1 minute followed by three-step cycling: denaturation at 948C for 30 seconds, annealing at a temperature optimized for each primer pair for 30 seconds, and extension at 728C for 30 seconds. After the requisite number of cycles (25 to 27 cycles), the reactions underwent a final extension at 728C for 5 minutes. Primer sequenses were SHP, forward (F) 5 0 -CTTCCTCAGGAACCT- Chromatin immunoprecipitation (ChIP) assay C2C12 or 293T cells were cotransfected with the designated expression constructs and -1.3 kb OG2-Luc reporter gene. Then, 48 hours after transfection, ChIP assays were performed as described previously. (28) The primer sequences for the Runx2- 
Recombinant adenovirus preparation and virus infection
The adenoviral vectors for full-length SHP (Ad-SHP) and SHP siRNA (Ad-siSHP) were described previously. (27, 28) Ad-BMP and Ad-Runx2 were described previously. (29) Briefly, cells were infected at the designated multiplicity of infection (MOI) using indicated viruses in no serum for 4 hours. Following viral infection, an equivalent volume of medium containing 4% FBS was added, and cells were incubated for an additional 24 hours before osteogenic medium treatment containing AA (50 mg/mL) and b-GP (5 mM) in the presence of BMP-2 (200 ng/mL).
Alkaline phosphatase activity and osteocalcin production assays ALP activity was measured in cell layers using p-nitrophenyl phosphate substrate as described previously. (31) X-ray and micro-computed tomographic (mCT) scanning C57BL/6J mice (male, 6 weeks old) were injected with a fixed dose of 5 Â 10 10 PN (particle number) of the designated adenoviral constructs in the thigh muscle: mock virus (n ¼ 3), Ad-BMP-2 (n ¼ 3), Ad-siSHP (n ¼ 3), and Ad-BMP-2 plus Ad-siSHP (n ¼ 3) diluted in PBS. Ectopic bone formation was monitored by radiographic apparatus (Hi-Tex, Osaka, Japan) at 35 kVp and 400 mA (2D). Microarchitecture of the femoral and tibial trabecular bone was investigated using mCT (Skyscan 1172, Skyscan, Kontich, Belgium) in cone-beam acquisition mode. The X-ray source was set at 50 kV and 200 A with a pixel size of 17.09 mm. Exposure time was 1.2 seconds. Four-hundred and fifty projections were acquired over an angular range of 180 degrees (angular step of 0.4 degree). The image slices were reconstructed using 3D CT analyzer software (CTAN, Skyscan). Trabecular morphometry was characterized by measuring the bone volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N), and trabecular separation (Tb.Sp). For static histomorphometry, the tibia from each mouse was removed and fixed in 4% paraformaldehyde in PBS at 48C, decalcified, dehydrated in progressive concentrations of ethanol, cleared in xylene, and embedded in paraffin. Quantification of osteoblasts and osteoclasts was performed in paraffin-embedded tissue, as described previously. (32) Animals SHP null (SHP À/À ) mice on a C57BL/6 and 129/Sv mixed background were backcrossed with C57BL/6 mice 10 times to generate congenic C57BL/6 SHP À/À mice, as described previously. (33) Age-matched male SHP À/À congenic and wild-type (WT) C57BL/6 mice were used throughout this study. All animal studies were carried out under the guidelines of the Chonnam National University Animal Care and Use Committee.
Statistical analysis
All experiments were repeated at least three times, and Student's t test was used to measure statistically significant differences among groups. Unless otherwise indicated, experimental data are expressed as means AE SD of triplicate independent samples.
Results
SHP gene expression is increased during osteoblast differentiation and regulated by BMP-2
SHP is expressed in various tissues and involved in a complex regulatory network comprised of a variety of NRs and transcription factors. (2, 3) To assess whether SHP might play a functional role in bone metabolism, the endogenous expression of SHP was examined in various progenitor cells. As shown in Fig. 1A , SHP is expressed in C3H10T1/2 pluripotent mesenchymal cells, C2C12 myoblastic cells, mouse primary osteoblasts, and MC3T3-E1 preosteoblastic cells. During the osteoblastic differentiation process, the expression levels of ALP and OC, which are typical osteoblast differentiation markers, were increased. (34) Importantly, the expression pattern of SHP was similar to that of ALP and OC after treatment with ascorbic acid (AA) and bglycerophosphate (b-GP), which are classic inducers of osteoblast differentiation (Fig. 1B) . The TGF-b superfamily member BMP-2 plays a central role during osteoblast differentiation. (12) To investigate the expression level of SHP during BMP-2-dependent osteoblasts differentiation, C2C12 cells were treated with BMP-2 in combination with AA and b-GP for 6 days. As shown in Fig. 1C , the addition of BMP-2 significantly induced the expression of SHP, in conjunction with other osteoblast differentiation markers, at a much earlier time point. These results indicate that the expression of SHP is temporally regulated during osteoblast differentiation, suggesting that SHP may play a specific role in bone development. As shown in Fig. 1C , the expression level of SHP also was increased by BMP-2, suggesting that BMP-2 is a potential regulator of SHP gene expression. Therefore, we examined SHP promoter activity in response to either treatment with exogenous BMP-2 or expression of various activated BMP receptors in C2C12 cells. As shown in Fig. 1D , SHP promoter reporter activity was increased by treatment with BMP-2 in a dose-dependent manner. To determine whether the increased SHP promoter activity is dependent on BMP signaling, constitutively active forms of TGF-b superfamily such as type IA activin receptor (ALK2), BMP type IA receptor (ALK3), TGF-b type I receptor (ALK5), and BMP type IB receptor (ALK6) were cotransfected with a SHP promoter reporter construct. The data showed that only ALK3 and -6, which are typical BMP receptors, activated SHP promoter activity (see Fig. 1E ), suggesting that BMP-2 is a potential regulator of SHP.
Inhibition of SHP expression represses expression of BMP2-induced osteoblast differentiation markers BMP-2 promotes osteoblast differentiation via regulation of the expression of various osteoblast-specific genes. (35, 36) To determine if there is a direct effect of SHP on BMP-2-induced osteoblast differentiation, SHP gene expression was inhibited by infecting C3H10T1/2 cells with an adenoviral vector expressing SHP small interfering RNA (Ad-siSHP). The expression of osteoblast differentiation markers then was observed in the presence of BMP-2. As shown in Figure 2A , adenovirus-mediated overexpression of BMP-2 in control cells induced the expression of osteoblast-specific genes such as ALP, OC, BSP, and Col I in conjunction with an increase in SHP expression, whereas expression of these differentiation marker genes was significantly repressed by Ad-siSHP. Interestingly, the inhibition of SHP also decreased the marker gene expression without BMP-2. As a functional analysis, we further confirmed the changes in ALP activity and OC production by Ad-siSHP-mediated inhibition of SHP expression in C2C12 cells. As shown in Figure 2B and C, BMP-2-induced ALP activity and OC production were significantly reduced by Ad-siSHP. Taken together, these results indicate that inhibition of SHP gene expression results in decreased expression of ALP, OC, BSP and Col I, all of which are involved in the regulation of osteoblast differentiation.
SHP regulates BMP-2-induced mineralization and ectopic bone formation Extracellular matrix mineralization is the most important phenomenon in bone formation and is regulated by various osteogenic factors. (37) The preceding results revealed that SHP regulates osteoblast differentiation. To verify the functional influences of SHP on BMP-2-induced mineralization, we infected C2C12 with Ad-SHP or Ad-siSHP in the presence or absence of BMP-2 and then assessed the amount of mineralization by alizarin red staining. As shown in Figure 3A , adenovirusmediated SHP overexpression moderately increased mineralized nodule formation even in the absence of BMP-2, whereas overexpression of SHP in combination with the addition of BMP-2 dramatically increased the amount of mineralization compared with BMP-2 alone. However, BMP-2-induced mineralization was significantly decreased by inhibition of SHP expression, even in the presence of added BMP-2. These results suggest that SHP is physiologically involved in BMP-2-induced mineralization. To confirm this result in a different cell line, we examined the effects of SHP expression on BMP-2-induced mineralized nodule formation in C3H10T1/2 cells. As shown in Figure 3B , Ad-BMP-2 dramatically increased mineralization, whereas inhibition of SHP expression with Ad-siSHP repressed the mineralization in a dose-dependent manner. In addition, BMP-2-induced OC production also was significantly decreased by Ad-siSHP during cell culture (see Fig. 3C ). These results indicate that SHP has a functional role in BMP-2-induced mineralization. It is well reported that subcutaneous or intramuscular administration of BMP-2 induces ectopic cartilage and bone formation. (12) To determine the effect of SHP on intramuscular bone formation in vivo, BMP-2-induced ectopic bone formation was analyzed in conjunction with Ad-siSHP intramuscular injection. Radiographic (X-ray, 2D) and mCT (3D) analysis revealed that adenovirusmediated BMP-2 expression profoundly induced ectopic bone formation in the thigh muscle, whereas inhibition of SHP expression significantly decreased the bone formation (see Fig. 3D ). Taken together, these results indicate that SHP regulates the expression of osteoblast-specific genes and the mineralization of potent osteoblastic cells that contribute to substantial bone formation.
Repressed osteoblast differentiation in SHP À/À mouse
To explore the physiologic effect of SHP in an animal model, we observed the endogenous expression profile of osteoblast marker genes and osteoblast differentiation in the SHP À/À mouse. As shown in Figure 4A , the expression levels of ALP, BSP, and osterix (OSX) were significantly decreased in SHP À/À mouse calvarial cells compared with WT mice. However, the expression levels of Col I and Runx2, a major transcription factor for osteoblast differentiation, were not significantly changed in Figure 4B and C, BMP-2-induced ALP activity and OC production were significantly decreased in SHP À/À mice compared with WT mice. In addition, mineralized nodule formation by BMP-2 was also decreased in SHP À/À mice (see Fig. 4D ), suggesting that the absence of SHP causes a defect in osteoblast differentiation.
These results indicate that endogenous SHP is substantially involved in osteoblast differentiation and mineralization. Osteoblast and osteoclast differentiations are sophisticated and well-orchestrated processes, and proper balance between both processes is critical for proper bone metabolism. (38) To examine whether SHP is involved in osteoclast differentiation, we examined the expression of osteoclast marker genes and tartrate resistant acid phosphatase (TRAP) staining from SHP À/À mouse bone marrow cells that are induced by receptor activator of NF-kB ligand (RANKL), a key inducer of osteoclast differentia- Fig. 3 . The effect of SHP on BMP-2-induced mineralization and ectopic bone formation. (A) SHP increased mineralized nodule formation induced by BMP-2. C2C12 cells were infected with the indicated adenovirus at an MOI of 100. The, 24 hours after infection, the medium was changed to a mineralizing medium containing AA and b-GP in the presence or absence of BMP-2 for 6 days. (B) Ad-siSHP decreased BMP-2-induced mineralized nodule formation. C3H10T1/2 cells were infected with the indicated adenovirus at 50 (þ) to 100 (þþ) MOI. Then, 24 hours after infection, the medium was changed to a mineralizing medium. During the cell culture, the medium was changed every other day. After 7 days, cells were fixed and stained with alizarin red stain (AR-S) solution, and the AR-S concentration was measured as described in ''Materials and Methods.'' The right panels of (A) and (B) depict the produced AR-S concentrations. (C) Ad-siSHP decreased BMP-2-induced OC production. At 3 and 6 days after adenoviral infection, the culture medium was harvested (by the same method as in the experiment described in panel B), and the amounts of OC secreted into the culture medium were measured as described in ''Materials and Methods.'' a, b, c ¼ p < .01. (D) Decreased BMP-2-induced ectopic bone formation by the inhibition of SHP expression. 5 Â 10 10 PNs (particle numbers) of each adenovirus was injected into thigh muscle of mice. Five weeks after injection, ectopic bone formation was analyzed by X-ray (2D) or mCT (3D). The white arrow indicates newly formed bone tissue. tion. As shown in Figure 4E and F, there was no clear difference in the typical morphology of osteoclasts and the expression patterns of marker genes such as osteoclast-associated receptor (OSCAR), TRAP, and nuclear factor of activated T cells (NFATc1) between WT and SHP À/À mouse bone marrow cells. These results indicate that SHP has no specific role in osteoclast differentiation and rather that it has more critical functions on osteoblast differentiation in bone metabolism.
Decreased bone mass in the SHP À/À mouse
To investigate the impact of SHP expression on direct bone formation, we compared the bone mass of WT and SHP À/À mice by mCT analysis and histomorphometric measurements in sections of tibiae collected at the ages of 1, 5 or 6, and 20 weeks, respectively. As shown in Figure 5A , bone mineral density (BMD) of tibiae from 5-and 20-week-old SHP À/À mice was significantly decreased compared with WT mice. Moreover, the bone mineral volume (BV/TV) also was decreased in same-aged SHP À/À mice (see Fig. 5B ). Fig. 5C-E) . Furthermore, the number of osteoblasts per bone surface was significantly reduced in SHP À/À mice (see Fig. 5F ). In addition, the growth plate of the SHP À/À mice had considerably fewer chondrocytes than WT mice, which have an elongated region of hypertrophic cartilage (see Fig. 5F , left panel). Interestingly, the histomorphometric analysis showed that the number of osteoclasts also was reduced in SHP À/À mice (see Fig. 5G ). 3D mCT measurements especially revealed a significant decrease in trabecular thickness in SHP À/À mice (see Fig. 5H and I). Collectively, these results suggest that SHP is involved in determining substantial bone architecture.
SHP physically interacts with Runx2 and regulates its transactivity
To determine the mechanism by which SHP promotes osteoblast differentiation, we examined the effect of SHP on the transactivity of Runx2 because BMP-2-Runx2 cascade is important for the differentiation of mesenchymal stem cells into the osteoblast lineage. (18) Moreover, bone-specific expression of OC is regulated principally by Runx2. (39) To examine whether SHP affects Runx2 function, the effect on Runx2 transactivity by SHP expression was analyzed in C3H10T1/2 cells. As shown in Figure 6A , the Runx2-dependent reporter activity of OG2-Luc was enhanced by overexpression of SHP. In C2C12 cells transfected with a 6ÂOSE-Luc, SHP also significantly increased Runx2 transactivity in a dose-dependant manner (see Fig. 6B ). To gain insights into the mechanism by which SHP increases Runx2 transactivity, we examined the physical interaction between SHP and Runx2 using an in vivo glutathione-S-transferase (GST) pulldown assay. As shown in Figure 6C , SHP physically interacted with Runx2 protein, showing that SHP activates Runx2 transactivity by direct interaction. To determine the interacting region of Runx2, we performed immunoprecipitation (IP) assay with different fragments of Runx2 proteins. As shown in Figure 6D , SHP strongly interacted with the Runt (R) domain, although there was weaker interaction with the amino terminus (N) of Runx2. To further examine whether there is any complex formation between SHP and Runx2 on their target gene promoter, ChIP assay was performed. As shown in Figure 6E , SHP interacted with Runx2, which bound to its target binding sequences of osteocalcin gene promoter. Consistent with these results, Ad-Runx2-mediated ALP activity was markedly repressed by the inhibition of SHP expression, whereas overexpression of SHP additively increased Runx2-dependent ALP activity (see Fig. 6F ). We further examined the Runx2 protein levels in primary osteoblasts of WT and SHP À/À mice. However, we could not detect any difference in Runx2 protein levels (data not shown). Taken together, these results indicate that SHP may regulate osteoblast differentiation through enhancement of Runx2 activity not via regulation of Runx2 protein level.
SHP regulates Runx2 transactivity via competition with HDAC4
Previous studies reported that various coactivators or corepressors interact with Runx2 to promote or repress Runx2 transactivity. (19, 21, 22) To examine whether SHP has any effect on transcriptional corepressors of Runx2, we used a transient transfection assay in C2C12 cells. The selected corepressors of Runx2, such as mSin3a, HDAC3, and HDAC4, significantly repressed Runx2 transactivity (data not shown). Among the corepressors, HDAC4 was the most strongly affected by SHP, which showed a significant recovering function for the HDAC4's repressive activity (Fig. 7A) . Moreover, SHP competed with HDAC4 for an influence over Runx2 transactivity (see Fig. 7B ), and inhibition of endogenous HDAC4 increased Runx2 transactivity (see Fig. 7C ), demonstrating that HDAC4 is a substantial corepressor of Runx2. A previous study reported that HDAC4 inhibits Runx2 from binding to its target gene, such as osteocalcin. (40) To further examine whether SHP competes with HDAC4 in vivo, we performed a ChIP assay in C2C12 cells. As shown in Figure 7D , expression of HDAC4 inhibited Runx2 DNA binding to the osteocalcin gene promoter, whereas expression of SHP relieved the repressed DNA binding of Runx2 in a dosedependent manner. These results indicate that SHP promotes Runx2 transactivity through competition with HDAC4.
Discussion
Osteoblast differentiation and bone matrix formation are finely tuned processes that are tightly regulated by a variety of transcription factors. Recently, it has been reported that several NRs regulate osteoblast differentiation via promotion of osteogenic gene expression. (23, 25) In this study, we investigated a role of the orphan NR SHP in bone formation. In osteoblastic cells, BMP-2 significantly induced SHP gene expression and induction of osteoblast differentiation as well as increased SHP promoter activity. As a member of the TGF-b superfamily, BMP-2 plays a central role in osteoblast differentiation and bone formation (12) through multiple downstream pathways, including the Smad pathway, which is initiated by phosphorylation of Smad proteins by type I receptors and the mitogen-activated protein kinase (MAPK) pathway. In either case, the ultimate consequence of BMP-2 signaling is the activation of gene transcription, which promotes osteoblast differentiation and bone formation. Therefore, the expression of SHP may be regulated by a certain mediator(s) that is involved in the BMP signaling pathway. To identify the potential mediator, we examined the effects of several regulators that are activated by BMP-2, such as Smads, JNK, c-Jun, Dlx5, Msx2, Runx2, and Osx, on SHP promoter activity. However, we were unable to identify an activator of the SHP promoter construct (data not shown). Meanwhile, some of our results revealed that AA and b-GP induced SHP expression in mouse calvarial cells (see Fig. 1B ) and that SHP overexpression by Ad-SHP also induced mineralization of osteoblastic cells, even in the absence of BMP-2 (see Fig. 3A ). promoter region. 293T cells were cotransfected with 3 mg of HA-SHP and Myc-Runx2 together with OG2 promoter. Then 48 hours after transfection, whole cell lysates were prepared and subjected to IP using respective antibodies, and the isolated DNA was analyzed by PCR. Primers were designed to amplify the Runx2-binding region on the OG2 promoter. Ten percent of the input whole cell lysate was used as the input control. ( F) The effects of SHP on the Runx2-mediated ALP activity. C3H10T1/2 cells were infected with the indicated adenovirus at an MOI of 100. Then, 24 hours after infection, the medium was changed to the osteogenic medium. Eight days later, ALP activity was determined as described previously. a, b ¼ p < .01.
Therefore, we cannot rule out the possible existence of either a BMP-2-independent modulator or an alternative BMP-2-dependent pathway that promotes SHP gene expression, and the possibility has lead us to begin the search for a novel SHP regulator. The fact that SHP expression is upregulated during osteoblast differentiation motivated us to speculate that SHP may have a positive role in bone metabolism, in contrast to its classic functions. In order to determine the endogenous role of SHP in bone differentiation, we observed BMP-2-induced osteoblast differentiation patterns in an SHP-deficient state becausee overexpression of SHP strongly augmented mineralized nodule formation induced by BMP-2 (see Fig. 3A ). The data demonstrated that inhibition of SHP expression reduced the expression of osteoblast-specific marker genes, mineralization of osteoblasts, and ectopic bone formation in the mouse. These results are in agreement with the results obtained from in vivo experiments in SHP À/À mice that revealed reduced osteoblast differentiation patterns and decreased bone mass. Interestingly, loss of SHP per se resulted in the reduction of osteogenesis regardless of BMP-2 existence. In addition, loss of SHP expression in primary osteoblasts, which show relatively high SHP expression (see Figs. 1A and 4A ), reduced the expression of ALP activity and mineralization without BMP-2 (see Fig. 4B-D) , but did not produce any significant changes in C2C12 cells, which show relatively low levels of SHP expression without BMP-2 (see Fig. 2B , C). This result indicates that SHP acts directly on osteogenesis with BMP-2-dependent or -independent signaling and suggest that SHP differentially regulates osteoblast differentiation in a cell-type-and a context-dependent manner.
In particular, trabecular BMDs of the tibia and femur were significantly decreased in SHP À/À mice, much more so than in the cortical bone. These results indicate that reduced bone mass may be due to decreased trabecular BMD. Meanwhile, a lack of SHP had no significant effect on bone mass in young mice (1 week after birth), which suggests that SHP is involved in the later stages of bone development. Recent study demonstrated that BMP-2 activity is required for postnatal bone physiology. (41) Therefore, our results indicate that the potential existence of a regulator of SHP expression or activation whose activity depends on developmental cues in connection with BMP-2 and that SHP may cooperate with BMP-2 for the late developmental stage in vivo. Bone metabolism is determined by the balance between osteoblastic cell function for bone formation and osteoclastic cell function for bone resorption, and various regulators act to maintain that balance. (42, 43) With regard to osteoclast differentiation, loss of SHP expression had no significant effect on cellular development or on the expression of osteoclast specific marker genes such as OSCAR, TRAP, and NFATc1 (see Fig. 4E, F) . However, our in vivo result showed that loss of SHP causes decreased osteoclast numbers as well as osteoblast numbers (see Fig. 5F , G). These results suggest that SHP has no direct effect on osteoclast differentiation, but it has an indirect effect on osteoclast number owing to the inhibition of osteoclastogenesis, which is partially regulated by mature osteoblasts. In general, SHP functions primarily as a transcriptional corepressor by interacting with various transcriptional factors, including nuclear receptors. (2) However, in this study, SHP was characterized as a positive regulator of bone differentiation, a finding that is inconsistent with its classic function. Among SHP target transcription factors, members of the PPAR family are known to be positive regulatory partners, and it has been reported that SHP is an endogenous enhancer of the transcriptional activity of PPARa (44) and that the activation of PPARg is due in part to the inhibition of NCoR activity by SHP.
Previously, we have investigated the relation between SHP and PPARg during adipogenic process in preadipocyte 3T3-L1. However, the expression of SHP was decreased during adipogenesis (data not shown). Thus this result suggests that SHP may not be involved in adipogenesis in connection with PPARg. Because SHP does not possess a DNA-binding domain, it may exert its role in bone formation through interaction with a specific coregulator. As a target regulator of SHP activity, we identified HDAC4, which blocks DNA binding of Runx2 to its target gene promoter. Our finding suggests that SHP uses a competition mechanism to regulate bone metabolism, which is similar to the regulation mechanism of SHP on PPARg transactivity. Recently, it was reported that SHP increases gene expression of cyclooxygenase-2 (COX-2) via the sequential transcriptional induction of a caudal-related homeobox gene (CDX1) in human gastric cancer cells. (46) With regard to its controversial regulatory propensity, these reports suggest that SHP may participate differently in various cellular functions depending on the cell type. Previous reports demonstrated that HDAC4 À/À mice exhibit a phenotype similar to that observed in mice with constitutive expression of Runx2 in chondrocytes, and HDAC4, which is expressed in prehypertrophic chondrocytes, regulates chondrocytes hypertrophy and endochondral bone formation by inhibiting the Runx2-binding activity. (40) In fact, endochonral bone formation begins with condensation of mesenchymal cells and their subsequent differentiation into chondrocytes, which organize into a template of the eventual bone comprised of a succession of proliferating, prehypertrophic, and hypertrophic regions. (47) As shown in Figure 5F , SHP À/À mice showed considerably fewer chondrocytes than WT mice. Thus our results also support the hypothesis that the transactivity of Runx2 is regulated by HDAC4 and that inhibition of HDAC4 promotes osteoblast differentiation and bone formation. This study presents new evidence that the orphan nuclear receptor SHP is a novel positive regulator of osteoblast differentiation and bone formation. These findings may open new areas for exploring the molecular mechanisms that underlie osteoblast differentiation by orphan nuclear receptors. Further, these findings also may contribute to the development of therapies based on the manipulation of SHP as an approach in the treatment of metabolic bone diseases such as osteoporosis. As of now, a natural ligand of SHP has not been identified, although one research group has proposed adamantyl-substituted retinoid-related molecules as potent regulators of SHP. (48) Thus it is important to pursue the identification of specific ligand(s) or agonist(s) of SHP, the identity of which will provide valuable tools for controlling bone metabolism.
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